Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156194 | 1.00 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL28809365 | 1.00 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL17169355 | 0.95 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL3645646 | 0.82 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL3647068 | 0.82 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL2842321 | 0.81 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL2844473 | 0.81 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL670331 | 0.81 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL6674308 | 0.79 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL20482096 | 0.79 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226929-B2 | Pharmaceutically active disubstituted triazine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20140179662-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| CN-103582482-A | Pharmaceutically active disubstituted triazine derivatives | LEAD DISCOVERY CENTER GMBH | 2014-02-12 | — | — | CN | disclosed |
| EP-2680852-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | Lead Discovery Center GmbH (DE) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012117048-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-09-07 | — | — | WO | disclosed |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179662-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | PDE5A, TESK2, PAK5 | SLC6A3 3354/4885SLC6A2 3814/4885SLC6A4 3823/4885 |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | SLC6A3 2728/4885SLC6A2 1666/4885SLC6A4 2772/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | SLC6A3 1563/4885SLC6A2 1163/4885SLC6A4 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.